Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L. lactis-GLP-1-DA@GN
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
L. lactis-GLP-1-DA@GN is a recombinant, engineered strain of Lactococcus lactis designed to express and secrete biologically active glucagon-like peptide 1 (GLP-1). This live biotherapeutic product is intended for oral administration, where the modified bacteria colonize the gut and continuously release GLP-1 over several days. GLP-1 is an incretin hormone that stimulates postprandial insulin secretion, reduces appetite, and slows gastric emptying—mechanisms beneficial in the management of diabetes and potentially obesity. The use of L. lactis as a delivery vehicle aims to overcome challenges associated with native GLP-1’s short half-life by providing sustained local production in the gastrointestinal tract[1][3]. The DA@GN component likely refers to additional modifications or encapsulation strategies for targeted delivery or enhanced stability, though specific details are not provided in available sources.
02
Targets
Beyond the preview
Go deeper on L. lactis-GLP-1-DA@GN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L. lactis-GLP-1-DA@GN.